Please ensure Javascript is enabled for purposes of website accessibility

Here's Why TransEnterix Is Tanking Today

By Brian Feroldi - Updated Apr 20, 2019 at 5:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares slump after the company reports a fourth quarter that missed the mark.

What happened

In response to fourth-quarter results, shares of TransEnterix (ASXC -3.63%), a medical device company focused on robotic surgery, fell as much as 22% in early-morning trading on Tuesday. Shares were down about 12% as of 10:15 a.m. EST.

So what

Management already provided investors with a sneak peek at its fourth-quarter results a few weeks ago at the annual J.P. Morgan Healthcare Conference. 

Here are the official numbers from the quarter:

  • Five Senhance Systems were sold during the fourth quarter. 
  • Revenue grew 120% to $7.5 million. That's slightly ahead of the $7.35 million that analysts were expecting. It was also a hair better than the $7.4 million management had previously predicted.
  • Adjusted net loss was $14.7 million, or $0.07 per share. That was worse than the $0.06 loss that Wall Street was expecting.
  • Cash balance at year end was $73 million. Management believes that it currently has enough capital on hand to fund operations into "late 2020."
Four Senhance robotic surgery arms

Image source: TransEnterix.

Here's a review of the numbers from the full year 2018:

  • 15 Senhance systems were sold.
  • Revenue grew 239% to $24.1 million.
  • Net loss was $61.8 million, or $0.30 per share.
  • Adjusted net loss was $50.4 million, or $0.24 per share. 

Traders appear to be reacting negatively to the higher-than-expected net loss for the quarter. The sell-off makes sense in light of the fact that TransEnterix's stock had gained more than 40% since the start of the year as of Monday.

Now what

TransEnterix's CEO Todd Pope called 2018 "a transformative year" for the company, since it was able to place 15 systems around the world and secure a number of regulatory wins. 

As for the year ahead, Pope stated, "We see a significant opportunity to leverage all of the progress we made in 2018 to continue to grow the adoption of the Senhance System globally."

This Fool agrees that 2018 was a successful year for TransEnterix, but there's no doubt that the company is still at least a few years away from reaching profitability. That means that investors can probably expect the company to perform yet another capital raise in the not-too-distant future. For that reason I'll continue to approach this stock with a wait-and-see mind-set.

Check out the latest TransEnterix earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.42 (-3.63%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.